ArticleFrontiers in pharmacology2024

Off-label use of Baricitinib improves moderate and severe atopic dermatitis in China through inhibiting MAPK and PI3K/Akt/mTOR pathway via targeting JAK-STAT signaling of CD4

Shuang Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.